Galderma has provided a progress update on its Biologics License Application (BLA) for relabotulinum toxin A, its proprietary neuromodulator candidate, currently under FDA review. While the company did not disclose a specific approval timeline, the filing remains active, positioning relabotulinum as a potential third major botulinum toxin option alongside Botox and Jeuveau in the U.S. market.
Regulatory
Galderma Updates Relabotulinum BLA Status With FDA — Third Neuromodulator Nears U.S. Approval
Regulatory progress on Galderma's botulinum toxin candidate; competitive pressure on pricing.
Relabotulinum moves through FDA review as a potential third neuromodulator option.
Relabotulinum differs from existing toxins in its manufacturing process and formulation, with clinical data suggesting a rapid onset and potentially longer duration. If approved, it would fragment the neuromodulator market further, intensifying price competition and forcing practices to evaluate unit economics across three platforms. Galderma's existing injectable portfolio (Restylane fillers, Dysport) gives it distribution leverage, but market share gains will hinge on rebate programs, clinical differentiation, and whether practices see meaningful clinical or economic advantage over entrenched competitors.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.